THE purpose of this report is to describe our experiences with ethamivan (vanillic diethylamide [Emivan]) in the therapy of disorders associated with respiratory depression.
Forty-three adult patients with clinical evidences of diffuse impairment of pulmonary air exchange were studied. These included 7 with barbiturate intoxication, 27 with severe chronic obstructive pulmonary emphysema, and 9 miscellaneous cases.
Arterial blood was sampled anaerobically using a Cournand needle in 10 of the subjects with pulmonary emphysema. Gas contents were obtained by the method of Van Slyke and Neill1 and the arterial CO2 tension (Paco2) calculated from a line chart based on the Henderson-Hasselbach equation,2 after the pH was determined with a Metrohm pH meter.
Our experiences with the 7 cases of barbiturate intoxication are summarized in Table 1. In the severely depressed patients (1 and 6), priming doses of 400 and 500 mg. of ethamivan were
Silipo S, Hagedorn C, Rosenstein IN, Baum GL. Experiences with Ethamivan, a New Respiratory Stimulant and Analeptic AgentA Preliminary Report. JAMA. 1961;177(6):378–380. doi:10.1001/jama.1961.73040320008005